Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 16, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2028

Conditions
Gastroesophageal AdenocarcinomaGastric Adenocarcinoma
Interventions
COMBINATION_PRODUCT

Arm 1: Adebrelimab Combined with Chemoradiotherapy Followed by Surgery

"* Adebrelimab: Given concurrently with chemotherapy, 1200mg by intravenous infusion every three weeks for four cycles.~* Chemotherapy: Oxaliplatin 130mg/m² on day 1 + Capecitabine 1000mg/m² bid (XELOX regimen), from day 1 to day 14, repeated every three weeks for four cycles;~* Radiotherapy: Unresectable limited metastatic lesions with SBRT; Potentially resectable lesions with low-dose radiotherapy.~* Surgery: Performed 3-5 weeks after the completion of conversion therapy."

Trial Locations (1)

210009

RECRUITING

Jiangsu cancer hospital, Nanjing

All Listed Sponsors
lead

Jiangsu Cancer Institute & Hospital

OTHER